The effect of montelukast, a leukotriene receptor antagonist, on the acetic acid-induced model of colitis in rats: Involvement of NO-cGMP-KATP channels pathway
Inflammatory bowel disease is a chronic autoimmune disorder that may involve entire gastrointestinal tract. The leukotrienes have a role as mediators in the pathophysiology of colitis. Here, we investigated the effect of a leukotriene receptor antagonist, montelukast, and also the role of the NO-cGM...
Saved in:
Main Authors: | , , , , , |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_9ed3ba6e03d24ce88aa1fdb6d628bf7b | ||
042 | |a dc | ||
100 | 1 | 0 | |a Behnam Ghorbanzadeh |e author |
700 | 1 | 0 | |a Mohammad Amin Behmanesh |e author |
700 | 1 | 0 | |a Roya Mahmoudinejad |e author |
700 | 1 | 0 | |a Mehdi Zamaniyan |e author |
700 | 1 | 0 | |a Shadi Ekhtiar |e author |
700 | 1 | 0 | |a Yousef Paridar |e author |
245 | 0 | 0 | |a The effect of montelukast, a leukotriene receptor antagonist, on the acetic acid-induced model of colitis in rats: Involvement of NO-cGMP-KATP channels pathway |
260 | |b Frontiers Media S.A., |c 2022-09-01T00:00:00Z. | ||
500 | |a 1663-9812 | ||
500 | |a 10.3389/fphar.2022.1011141 | ||
520 | |a Inflammatory bowel disease is a chronic autoimmune disorder that may involve entire gastrointestinal tract. The leukotrienes have a role as mediators in the pathophysiology of colitis. Here, we investigated the effect of a leukotriene receptor antagonist, montelukast, and also the role of the NO-cGMP-KATP channel pathway in acetic acid-induced colitis. Rectal administration of acetic acid (4%) was used for induction of colitis in rats. To investigate our hypothesis, the rats were intraperitoneally pre-treated with L-NAME (NOS inhibitor), L-arginine, sildenafil, methylene blue, glibenclamide, or diazoxide 15 min before treatment with montelukast (5-20 mg/kg, i. p.), for three consecutive days. Then, microscopic, macroscopic, and inflammatory parameters were evaluated. Montelukast reduced the microscopic and macroscopic damage induced by acetic acid. Montelukast also reduced the level of IL-1β and TNF-α. We also showed that the effects of montelukast were significantly attenuated by L-NAME, methylene blue (guanylate cyclase inhibitor), and an ATP-sensitive potassium channel blocker (glibenclamide). Also, the administration of L-arginine, sildenafil, and diazoxide before montelukast produced protective effect. In conclusion, the pathway of the NO-cGMP-KATP channel is involved in the protective effect of montelukast in acetic acid-induced colonic tissue damage. | ||
546 | |a EN | ||
690 | |a montelucast | ||
690 | |a nitric oxide | ||
690 | |a cGMP | ||
690 | |a cyclic guanosine monophosphate | ||
690 | |a KATP channels | ||
690 | |a rats | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Frontiers in Pharmacology, Vol 13 (2022) | |
787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fphar.2022.1011141/full | |
787 | 0 | |n https://doaj.org/toc/1663-9812 | |
856 | 4 | 1 | |u https://doaj.org/article/9ed3ba6e03d24ce88aa1fdb6d628bf7b |z Connect to this object online. |